Lao People's Democratic RepublicTuberculosis profile
Population  2014 6.7 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.7 (2.4–5.2) 55 (36–78)
Mortality (HIV+TB only) 0.28 (0.21–0.35) 4.1 (3.2–5.2)
Prevalence  (includes HIV+TB) 31 (20–44) 464 (303–659)
Incidence  (includes HIV+TB) 13 (9.5–16) 189 (141–244)
Incidence (HIV+TB only) 0.5 (0.34–0.68) 7.4 (5.1–10)
         
Case detection, all forms (%) 35 (27–47)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 4.5 (2.6–6.4) 23 (20–26)
MDR-TB cases among notified pulmonary
TB cases
170 (99–240) 64 (56–72)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 105   198
Pulmonary, clinically diagnosed 685   0
Extrapulmonary 408   0
       
Total new and relapse 4 396    
Previously treated, excluding relapses 86    
Total cases notified 4 482    
Among 4 162 new and relapse cases:
73 (2%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 671 (22%) 68 (24%) 739
Laboratory-confirmed RR-/MDR-TB cases     24
Patients started on MDR-TB treatment ***     25
TB/HIV 2014 Number (%)
TB patients with known HIV status 3 390 (76)
HIV-positive TB patients 258 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 200 (78)
HIV-positive people screened for TB 119  
HIV-positive people provided with IPT 715  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (87) 3 937
Previously treated cases, excluding relapse, registered in 2013 (50) 46
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (38) 13
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 3.9
% Funded domestically 5%
% Funded internationally 79%
% Unfunded 16%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-29 Data: www.who.int/tb/data